Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CREATES Act Will Not Lead To Frivolous Lawsuits, Says AAM's Davis

Executive Summary

Association for Accessible Medicines' Davis tries to counter concerns that the long-stalled measure would incentivize lawsuits against brand companies; witnesses at a House subcommittee hearing on drug pricing legislation also testified that the BLOCKING Act would create an overly broad and complicated framework for triggering 180-day exclusivity.

Advertisement

Related Content

Trump FY 2020 Budget Renews Push To Reform 180-Day Exclusivity
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
REMS Abuse Website: Has It Changed The Behavior Of Innovators?
CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor
Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?

Topics

Related Companies

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140160

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel